P. Fouqueray

发表

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

D. Moller, S. Bolze, M. Kergoat, 2020, bioRxiv.

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study

K. Cusi, D. Moller, J. Dubourg, 2021, Cell reports. Medicine.

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity

Ajit S. Divakaruni, A. W. Czarnik, L. V. D. van der Ploeg, 2021, Hepatology communications.

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin

E. Fontaine, D. Moller, G. Vial, 2022, Physiological reports.

Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients

H. Lebovitz, V. Pīrāgs, P. Fouqueray, 2012, Diabetes, obesity & metabolism.

Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes

X. Leverve, H. Lebovitz, C. Wollheim, 2011 .

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial

K. Ueki, J. Dubourg, J. Grouin, 2020, Diabetes, obesity & metabolism.

Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy

D. Moller, T. Nagaraja, Jaspreet Singh, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

K. Cusi, D. Moller, N. Alkhouri, 2021, The lancet. Gastroenterology & hepatology.

Lack of Drug–Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers

J. Dubourg, S. Bolze, P. Fouqueray, 2020, European Journal of Drug Metabolism and Pharmacokinetics.

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects

S. Bolze, P. Fouqueray, Clémence Chevalier, 2022, Clinical Drug Investigation.

Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period

H. Watada, Caroline Reilhac, J. Dubourg, 2021, Diabetes, obesity & metabolism.

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial

K. Kaku, J. Dubourg, J. Grouin, 2021, Diabetes, obesity & metabolism.

Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents.

K. Petersen, G. Shulman, R. Kibbey, 2016, American journal of physiology. Endocrinology and metabolism.

Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial

K. Ueki, J. Dubourg, J. Grouin, 2021, Diabetes Care.

In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans

P. Fouqueray, Chevalier Clémence, Bolze Sébastien, 2020, Drug Metabolism and Disposition.

Effects of the anti-diabetic imeglimin in hyperglycemic mice with septic shock

M. Georgieff, E. Fontaine, P. Radermacher, 2012, Critical Care.

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity

G. Pacini, A. Mari, V. Pīrāgs, 2022, Endocrinology, diabetes & metabolism.

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects

S. Bolze, P. Fouqueray, Clémence Chevalier, 2022, Clinical Drug Investigation.

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

E. Fontaine, D. Moller, A. Borel, 2020, Diabetes, obesity & metabolism.

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

H. Lebovitz, S. Inzucchi, C. Bailey, 2013, Diabetes Care.

Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment

J. Dubourg, S. Bolze, P. Fouqueray, 2020, Clinical Pharmacokinetics.

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy

H. Lebovitz, S. Inzucchi, C. Bailey, 2014, Diabetes Care.

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

D. Moller, S. Bolze, M. Kergoat, 2020, bioRxiv.

Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects

S. Bolze, P. Fouqueray, Sandrine Perrimond-Dauchy, 2020, Clinical Pharmacokinetics.

Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes

G. Pacini, A. Mari, S. Bolze, 2015, Diabetes, obesity & metabolism.

Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration

E. Fontaine, D. Détaille, A. Borel, 2016, Cell Death Discovery.

Evaluation of PXL065 - Deuterium-Stabilized (R)-Pioglitazone in NASH Patients: a Phase 2 randomized placebo-controlled trial (DESTINY-1).

K. Cusi, P. Bedossa, D. Moller, 2023, Journal of hepatology.

Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus

J. Dubourg, S. Bolze, P. Fouqueray, 2020, European Journal of Clinical Pharmacology.

IMEGLIMIN, A NEW MITOCHONDRIA-TARGETED AGENT FOR TYPE 2 DIABETES TREATMENT

S. Bolze, S. Hallakou-Bozec, P. Fouqueray, 2015 .